127 related articles for article (PubMed ID: 2196115)
1. In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.
Chaney SG; Wyrick S; Till GK
Cancer Res; 1990 Aug; 50(15):4539-45. PubMed ID: 2196115
[TBL] [Abstract][Full Text] [Related]
2. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.
Chaney SG; Gibbons GR; Wyrick SD; Podhasky P
Cancer Res; 1991 Feb; 51(3):969-73. PubMed ID: 1988140
[TBL] [Abstract][Full Text] [Related]
3. Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.
Gibbons GR; Wyrick S; Chaney SG
Cancer Res; 1989 Mar; 49(6):1402-7. PubMed ID: 2924297
[TBL] [Abstract][Full Text] [Related]
4. Effects of diethyldithiocarbamate (DDTC) on the plasma biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in Fischer 344 rats.
Carfagna PF; Wyrick SD; Holbrook DJ; Chaney SG
J Biochem Toxicol; 1991; 6(1):71-80. PubMed ID: 1652641
[TBL] [Abstract][Full Text] [Related]
5. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.
Mauldin SK; Gibbons G; Wyrick SD; Chaney SG
Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses.
Carfagna PF; Poma A; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1991; 27(5):335-41. PubMed ID: 1998992
[TBL] [Abstract][Full Text] [Related]
7. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
8. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.
Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386
[TBL] [Abstract][Full Text] [Related]
9. Biotransformations of oxaliplatin in rat blood in vitro.
Luo FR; Wyrick SD; Chaney SG
J Biochem Mol Toxicol; 1999; 13(3-4):159-69. PubMed ID: 10098901
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
[TBL] [Abstract][Full Text] [Related]
12. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
Mauldin SK; Husain I; Sancar A; Chaney SG
Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
Luo FR; Wyrick SD; Chaney SG
Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
[TBL] [Abstract][Full Text] [Related]
15. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.
Luo FR; Yen TY; Wyrick SD; Chaney SG
J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):345-56. PubMed ID: 10219677
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intravenously injected [3H]tetrachloro(D,L-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin) in mice.
Kido Y; Khokhar AR; Siddik ZH
Drug Metab Dispos; 1992; 20(5):673-8. PubMed ID: 1358571
[TBL] [Abstract][Full Text] [Related]
17. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
[TBL] [Abstract][Full Text] [Related]
18. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):29-38. PubMed ID: 10367746
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.
Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV
Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402
[TBL] [Abstract][Full Text] [Related]
20. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
